Alantra strengthens its pharma sector focus with senior appointment

Alantra, the global mid-market investment banking firm, has appointed Anthony Harrington as a Partner and key member of its healthcare advisory team.  A leading advisor to the pharma services sector, Anthony has over fifteen years of M&A experience in the healthcare sector having worked on more than 40 M&A transactions and a variety of strategic advisory projects for clients in the UK, US, Europe and Asia.  Anthony will be based in Alantra’s London office.

Anthony’s appointment underlines Alantra’s strategy of investing in its sector routes to market. It comes during an active period for the healthcare team as global M&A volumes within the healthcare sector remain strong.  There were 165 healthcare deals completed globally in the first half of 2019, of which 53 deals were completed within the pharmaceuticals sub-sector.

Prior to joining Alantra, Anthony held positions in the healthcare teams at Results International, Bear Sterns and Rothschild. He has advised high-profile pharma services business including Cherry Healthcare on its sale to Avenir Global, Prescient Healthcare Group on the investment from Baird Capital, Lucid Group on the investment from LDC, STEM on its £84m sale to UDG PLC and Hive on its £50m sale to St Ives PLC. Anthony also sits on the awards judging panel for healthcare industry body, Communiqué.

As a key member of Alantra’s international Healthcare sector team, Anthony will work closely with business owners and management teams in the pharma services sector as well as financial sponsors, generating off-market opportunities, providing buy-side advice and maximising value in sale processes.

Anthony Harrington, Partner at Alantra, commented: “Fast-growing healthcare companies seeking investment or other strategic solutions are increasingly presented with a muddied environment. The shrinking global market means they are being approached by strategic acquirers from around the world, a huge number of financial investors are seeking to invest into the sector, and there are numerous other options available, from angel investors to specialist debt providers. Navigating these options requires a combination of deep sector expertise – especially in a sector as complex and dynamic as healthcare – and broad experience in all facets of the corporate finance world. As the leading global mid-market advisory firm, Alantra’s engaged global team of senior advisors is perfectly positioned to meet these needs and I am delighted to be joining them.”

Andy Currie, Managing Partner of Alantra’s UK advisory business, said: “Deep sector experience and senior-led transaction advice are key elements of the Alantra offering.  This marries well with the needs of our healthcare clients and it is great to be able to welcome Anthony to the team. We are absolutely committed to attracting the highest quality talent and investing behind our people in our chosen markets as we grow the Alantra business both in the UK and globally.”